Cover Image
市場調查報告書

神經纖維瘤第一型 (Recklinghausen disease):全球臨床實驗趨勢

Neurofibromatoses Type I (Von Recklinghausen's Disease) Global Clinical Trials Review, H2, 2015

出版商 GlobalData 商品編碼 339707
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
神經纖維瘤第一型 (Recklinghausen disease):全球臨床實驗趨勢 Neurofibromatoses Type I (Von Recklinghausen's Disease) Global Clinical Trials Review, H2, 2015
出版日期: 2015年08月19日 內容資訊: 英文 91 Pages
簡介

本報告提供神經纖維瘤第一型 (Recklinghausen disease) 臨床實驗相關之最新趨勢分析,提供您各地區的主要國家臨床實驗數量,臨床實驗的各階段進展,實驗對象採用狀況,有潛力的贊助商,各企業和研究機關的研究進展,以及潛力藥劑比較等資訊。

簡介

  • 神經纖維瘤第一型 (Recklinghausen disease)
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要國家的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量

G7各國臨床實驗數量:遺傳性疾病治療藥臨床實驗上神經纖維瘤第一型 (Recklinghausen disease) 的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

神經纖維瘤第一型 (Recklinghausen disease) 治療藥臨床實驗主要的參與企業

有潛力的藥劑

臨床實驗簡介

  • 主要企業臨床實驗概要
    • AstraZeneca Plc
    • Novartis AG
    • ZonMw
    • Sarcoma Alliance for Research through Collaboration
    • Quintiles Transnational Holdings Inc.
    • Pfizer Inc.
    • Kolltan Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • 第一三共
    • Array BioPharma Inc.
  • 有代表性的研究機關·醫院臨床實驗概要
    • National Cancer Institute
    • University of Alabama at Birmingham
    • Massachusetts General Hospital
    • Assistance Publique - Hopitaux de Paris
    • Central Manchester University Hospitals NHS Foundation Trust
    • Centre Hospitalier Universitaire de Nantes
    • Erasmus MC
    • Foundation IRCCS Neurological Institute Carlo Besta
    • Hospices Civils de Lyon
    • Indiana University

5個有代表性的臨床實驗簡介

附錄

目錄
Product Code: GDHC2833CTIDB

GlobalData's clinical trial report, "Neurofibromatoses Type I (Von Recklinghausen's Disease) Global Clinical Trials Review, H2, 2015" provides an overview of Neurofibromatoses Type I (Von Recklinghausen's Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Neurofibromatoses Type I (Von Recklinghausen's Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Neurofibromatoses Type I (Von Recklinghausen's Disease)
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Clinical Trials by G7 Countries: Proportion of Neurofibromatoses Type I (Von Recklinghausen's Disease) to Genetic Disorders Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Neurofibromatoses Type I (Von Recklinghausen's Disease)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • AstraZeneca Plc
      • Clinical Trial Overview of AstraZeneca Plc
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • ZonMw
      • Clinical Trial Overview of ZonMw
      • Sarcoma Alliance for Research through Collaboration
      • Clinical Trial Overview of Sarcoma Alliance for Research through Collaboration
      • Quintiles Transnational Holdings Inc.
      • Clinical Trial Overview of Quintiles Transnational Holdings Inc.
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Kolltan Pharmaceuticals, Inc.
      • Clinical Trial Overview of Kolltan Pharmaceuticals, Inc.
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Daiichi Sankyo Company, Limited
      • Clinical Trial Overview of Daiichi Sankyo Company, Limited
      • Array BioPharma Inc.
      • Clinical Trial Overview of Array BioPharma Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • University of Alabama at Birmingham
      • Clinical Trial Overview of University of Alabama at Birmingham
      • Massachusetts General Hospital
      • Clinical Trial Overview of Massachusetts General Hospital
      • Assistance Publique - Hopitaux de Paris
      • Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
      • Central Manchester University Hospitals NHS Foundation Trust
      • Clinical Trial Overview of Central Manchester University Hospitals NHS Foundation Trust
      • Centre Hospitalier Universitaire de Nantes
      • Clinical Trial Overview of Centre Hospitalier Universitaire de Nantes
      • Erasmus MC
      • Clinical Trial Overview of Erasmus MC
      • Foundation IRCCS Neurological Institute Carlo Besta
      • Clinical Trial Overview of Foundation IRCCS Neurological Institute Carlo Besta
      • Hospices Civils de Lyon
      • Clinical Trial Overview of Hospices Civils de Lyon
      • Indiana University
      • Clinical Trial Overview of Indiana University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Region, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015*
  • Proportion of Neurofibromatoses Type I (Von Recklinghausen's Disease) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Suspended Clinical Trials, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by ZonMw, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarcoma Alliance for Research through Collaboration, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Quintiles Transnational Holdings Inc., 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Kolltan Pharmaceuticals, Inc., 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Array BioPharma Inc., 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Alabama at Birmingham, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Central Manchester University Hospitals NHS Foundation Trust, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Centre Hospitalier Universitaire de Nantes, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Foundation IRCCS Neurological Institute Carlo Besta, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospices Civils de Lyon, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials Market, Global, Clinical Trials by Indiana University, 2015*

List of Figures

  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Proportion of Neurofibromatoses Type I (Von Recklinghausen's Disease) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Neurofibromatoses Type I (Von Recklinghausen's Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top